FiltersReset Filters

With box warnings

Without box warnings

Branded

Generic

11 results

daunorubicin hydrochloride
(daunorubicin hydrochloride)
Hisun Pharmaceuticals USA, Inc.
Usage: Daunorubicin hydrochloride injection is indicated for remission induction in adults with acute nonlymphocytic leukemia (including myelogenous, monocytic, erythroid) and in children and adults with acute lymphocytic leukemia, used in combination with other approved anticancer drugs.
daurismo
(glasdegib)
Pfizer Laboratories Div Pfizer Inc
Usage: DAURISMO is indicated for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients aged 75 or older, or those with comorbidities that prevent the use of intensive induction chemotherapy, when used in combination with low-dose cytarabine.
idhifa
(enasidenib mesylate)
Celgene Corporation
Usage: IDHIFA is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have an IDH2 mutation, confirmed by an FDA-approved test.
mylotarg
(gemtuzumab ozogamicin)
Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.
Usage: MYLOTARG is indicated for treating newly-diagnosed CD33-positive acute myeloid leukemia (AML) in adults and pediatric patients aged 1 month and older, as well as for relapsed or refractory CD33-positive AML in patients aged 2 years and older.
onureg
(azacitidine)
Celgene Corporation
Usage: ONUREG is indicated for the continued treatment of adults with acute myeloid leukemia who have achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) after intensive induction chemotherapy and are unable to complete intensive curative therapy.
rezlidhia
(olutasidenib)
Rigel Pharmaceuticals, Inc.
Usage: REZLIDHIA is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a susceptible isocitrate dehydrogenase-1 (IDH1) mutation, as confirmed by an FDA-approved test.
tibsovo
(ivosidenib)
Servier Pharmaceutical LLC
Usage: TIBSOVO is indicated for treating newly diagnosed acute myeloid leukemia (AML) with an IDH1 mutation, relapsed or refractory AML, relapsed or refractory myelodysplastic syndromes (MDS), and previously treated locally advanced or metastatic cholangiocarcinoma with an IDH1 mutation in adults.
vanflyta
(QUIZARTINIB)
Daiichi Sankyo Inc.
Usage: VANFLYTA is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 ITD-positive. It is used in combination with chemotherapy for induction and consolidation, and as maintenance monotherapy post-consolidation. Not for use after allogeneic stem cell transplantation.
venclexta
(Venetoclax)
AbbVie Inc.
Usage: VENCLEXTA is indicated for treating adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It is also used in combination with azacitidine, decitabine, or low-dose cytarabine for newly diagnosed acute myeloid leukemia (AML) in adults aged 75 or older, or with significant comorbidities.
vyxeos
((daunorubicin and cytarabine) liposome)
Jazz Pharmaceuticals, Inc.
Usage: VYXEOS is indicated for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients aged 1 year and older.

Medications for Leukemia Acute Myeloid Leukemia Aml

daunorubicin hydrochloride

daurismo

idhifa

mylotarg

onureg

rezlidhia

tibsovo

vanflyta

venclexta

vyxeos